Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
Tue, 06/18/19 - 11:46 pm
Tags:
AbbVie, Humira, Merck, Keytruda, Eliquis, Bristol-Myers Squibb, Imbruvica, Opdivo, Revlimid, Celgene
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Pharmaforum
Fri, 06/14/19 - 06:22 pm
Tags:
Eli Lilly, Taltz, AbbVie, Humira, psoriatic arthritis
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Wed, 06/12/19 - 09:45 am
Tags:
Vertex Pharmaceuticals, VX-445, tezacaftor/ivacaftor, AbbVie, upadacatinib, Daiichi Sankyo, trastuzumab deruxtecan, Celgene, liso-cel, Novartis, LY3298176
AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
Fierce Pharma
Mon, 05/20/19 - 11:07 pm
Tags:
AbbVie, Humira, Skyrizi, drug launches, psoriasis, drug pricing, formulary
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Motley Fool
Sun, 05/19/19 - 04:05 pm
Tags:
Alexion, Ultomiris, AbbVie, Upadacitinib, risankizumab, Aimmune Therapeutics, AR-101, Bluebird Bio, LentiGlobin
AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial
Marketwatch
Fri, 05/17/19 - 10:54 am
Tags:
AbbVie, Depatux-M, glioblastoma, cilnical trials
AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva
Fierce Pharma
Thu, 05/16/19 - 10:53 am
Tags:
AbbVie, Roche, Venclexta, CLL, small lymphocytic leukemia
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
Marketwatch
Tue, 05/14/19 - 09:31 am
Tags:
AbbVie, biosimilars, Humira, patents, Boehringer Ingelheim
Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown
Fierce Biotech
Tue, 05/14/19 - 09:26 am
Tags:
Myovant Sciences, Relugolix, clinical trials, uterine fibroids, AbbVie, Elagolix
Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises
Endpoints
Tue, 05/7/19 - 10:15 am
Tags:
AstraZeneca, Calquence, clinical trials, chronic lymphocytic leukemia, AbbVie, JNJ, Imbruvica
Why AbbVie Is in Better Shape Than You Might Think
Motley Fool
Sun, 04/28/19 - 12:26 pm
Tags:
AbbVie
Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline
Marketwatch
Sun, 04/28/19 - 12:16 pm
Tags:
AbbVie, earnings, Humira, generics
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
Biopharma Dive
Fri, 04/26/19 - 07:45 pm
Tags:
AbbVie, hepatitis C, Netflix model, Washington state
Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun
Fierce Pharma
Thu, 04/25/19 - 07:16 pm
Tags:
AbbVie, Humira, biosimilars, earnings
What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings
Motley Fool
Thu, 04/25/19 - 07:15 pm
Tags:
AbbVie, earnings, Humira
AbbVie successor to Humira in psoriasis gains FDA approval
BioCentury
Tue, 04/23/19 - 10:59 pm
Tags:
AbbVie, Humira, psoriasis, Skyrizi, FDA
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Fierce Pharma
Tue, 04/23/19 - 05:32 pm
Tags:
AbbVie, Celgene, JNJ, Merck, Pfizer, Vertex Pharmaceuticals, investors, executive pay
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Mon, 04/22/19 - 10:34 am
Tags:
Concert Pharmaceuticals, Horizon Pharma, Edwards Lifesciences, Zimmer Biomet, Genfit, Precision Biosciences, Boston Scientific, AbbVie, Alexion, Bristol-Myers Squibb, Baxter, Biomarin, AtriCure, Biogen, Seattle Genetics, IPOs, earnings
AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect
Motley Fool
Mon, 04/22/19 - 10:23 am
Tags:
AbbVie, earnings
3 Cancer Treatment Stocks on a Growth Trend
Motley Fool
Sun, 04/21/19 - 10:33 pm
Tags:
Geron, AbbVie, Exelixis, cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.